ArticleJournal of pharmaceutical policy and practice2023
Expanding access to high-cost medicines under the Universal Health Coverage scheme in Thailand: review of current practices and recommendations.
Article in Journal of pharmaceutical policy and practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Multi-Stakeholder Primary Health Care for Migrant Populations in Thailand's Border Regions: A Qualitative Study of Barriers and Opportunities.Journal of immigrant and minority health · 2026Article
- The landscape of adult obesity in Malaysia: a mapping of evidence and contemporary narrative review.The Lancet regional health. Western Pacific · 2026Review
- Integrating Equity in Topic Selection for Orphan Medicinal Products: Policy Implications for Health Technology Assessment in Rare Diseases.Applied health economics and health policy · 2026Review
- Optimal insurance coverage and pricing of outpatient drugs in Iran: a cost- and chronicity-based adaptation of the vertical equity model.International journal for equity in health · 2026Article
- Harnessing health economic evaluation for policy and practice.Communications medicine · 2026Review
- Exploring alternative funding mechanisms to improve patient access to innovative medicines.BMC health services research · 2026Article
- Comparative Cost Evaluation of Managed Entry Agreement Techniques Using Real-World Data from High-Cost Anticancer Drugs in Thailand.Journal of market access & health policy · 2026Article
- Disease Burden and Disparities of Care for Kidney Health in the Asian Pacific Region: Summary Report From the Diversity and Equity Committee of APSN.Nephrology (Carlton, Vic.) · 2026Review
- Health Technology Assessment Guidelines and Recommendations Across European Union Countries and the United Kingdom in Rare Disease and Paediatric Populations.Applied health economics and health policy · 2026Article
- Supporting evidence-informed policy: a multidimensional impact analysis of health technology assessment in Thailand.Frontiers in public health · 2026Article
- Deconstructing Pharmaceutical Prices in a Government-Controlled Market: A Hedonic Regression Analysis of B2G Procurement in Thailand.Health services insights · 2026Article
- Can development alone save lives? trends and forecasts of congenital heart anomalies-attributable premature mortality in ASEAN.Frontiers in cardiovascular medicine · 2026Article
- Assessing the Value for Money of Enzyme Replacement Therapy in Gaucher Disease Types 1 and 3b: Can Expanded Coverage Be Justified?PharmacoEconomics - open · 2025Article
- Onasemnogene Abeparvovec Gene Therapy and Risdiplam for the Treatment of Spinal Muscular Atrophy in Thailand: A Cost-Utility Analysis.Applied health economics and health policy · 2025Article
- Early health technology assessment of tongue swab for non-sputum based pulmonary tuberculosis diagnosis in Thailand.The Lancet regional health. Southeast Asia · 2025Article
- Establishing a Dedicated Fund to Improve Patient Access to Cancer Medicines: Key Considerations and Policy Implications for Thailand Comment on "Scoping Review of International Experience of a Dedicated Fund to Support Patient Access to Cancer Drugs: Policy Implications for Thailand".International journal of health policy and management · 2025Article
- Health Benefit Package Revision Is an Art as Much as a Science - Lessons Learned on the Organization of the Appraisal Phase.International journal of health policy and management · 2025Article
- Beyond cost: a value-based framework for biosimilar procurement in emerging markets - the Thai experience.Journal of pharmaceutical policy and practice · 2025Article
- Budget Impact and Cost-Benefit Analyses of Sodium-Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure in Thailand.ClinicoEconomics and outcomes research : CEOR · 2025Article
- Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and Challenges.Applied health economics and health policy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThere has been an increasing demand to reimburse high-cost medicines, through public health insurance schemes in Thailand.
methodsA mixed method approach was employed. First, a rapid review of select high-income countries was conducted, followed by expert consultations and an in-depth review of three countries: Australia, England and Republic of Korea to understand reimbursement mechanisms of high-cost medicines. In Thailand, current pathways for reimbursing high-cost medicines reviewed, the potential opportunity cost estimated, and stakeholder consultations were conducted to identify context specific considerations.
resultsHigh-income countries reviewed have implemented a variety of pathways and mechanisms for reimbursing high-cost medicines under specific eligibility criteria, listing processes, varying cost-effectiveness thresholds and special funding arrangements. In Thailand, high-cost medicines that do not offer good value-for-money are excluded from the reimbursement process. A framework for reimbursing high-cost medicines that are not cost-effective at the current willingness-to-pay threshold was proposed for Thailand. Under this framework, specific criteria are proposed to determine their eligibility for reimbursement such life-saving nature, treatment of conditions with no alternative treatment options, and affordability.
conclusionHigh-cost medicines may become eligible for reimbursement through alternative mechanisms based on specific criteria which depend on each context. The application of HTA methods and processes is important in guiding these decisions to support sustainable access to affordable healthcare in pursuit of Universal Health Coverage (UHC).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.